Aramark Common Stock vs Charles River Laboratories Intl. Inc — how do they compare? Aramark Common Stock trades at $52.56 (market cap $13.86B), while Charles River Laboratories Intl. Inc trades at $345.37 (market cap $16.49B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Aramark Common Stock pays a 0.91% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Aramark Common Stock for 17 Days and Charles River Laboratories Intl. Inc for 34 Days on average.
| ARMK | CRL | |
|---|---|---|
Market Cap | $13.86B | $16.49B |
Volume | 3,242,863 | 808,452 |
Sector | Industrials | Health |
52-Week High | $62.39 | $345.37 |
52-Week Low | $36.04 | $149.93 |
Typical Hold Time | 17 Days | 34 Days |
Enterprise Value | $19.82B | $19.32B |
Dividend Yield | 0.91% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Charles River Laboratories (CRL) trades at $345.37, up 1.68% on the day, with strong technical momentum as price approaches resistance near $348. The stock shows consistent earnings beats in recent quarters but faces fundamental challenges with negative net income margins (-5.96%) and elevated valuation multiples (P/E 684.85). Recent investor day highlighted strategic growth targets of 5-7% revenue growth and $300M savings by 2030.
While analyst sentiment remains bullish (73% buy ratings) and technicals suggest near-term strength, the stock trades above consensus price target ($308.36) with stretched valuations. Key risks include profitability challenges, NHP cost volatility, and execution risks on growth targets. The current price near 52-week highs requires careful risk management despite positive momentum.
Trailing returns across standard periods
Aramark provides food, facilities, and hospitality services for education, healthcare, business, and sports and entertainment clients.
Read more on ARMK →Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →